SCYNEXIS Inc (SCYX) stock
SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3076% below fair value
$2.38−0.23 (-8.64%)
Close on Nov 20, 2026Market cap $23.68MP/E –Yield –
Scynexis free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Scynexis's free cash flow for the twelve months ending Dec 31, 2021 was -$54.56M. For fiscal 2021 it was -$54.56M. The highest annual figure on record is -$4.74M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | -$54.56M | – |
| FY2020 | Dec 31, 2020 | -$49.36M | – |
| FY2019 | Dec 31, 2019 | -$38.12M | – |
| FY2018 | Dec 31, 2018 | -$28.89M | – |
| FY2017 | Dec 31, 2017 | -$24.56M | – |
| FY2016 | Dec 31, 2016 | -$29.38M | – |
| FY2015 | Dec 31, 2015 | -$25.13M | – |
| FY2014 | Dec 31, 2014 | -$10.18M | – |
| FY2013 | Dec 31, 2013 | -$4.74M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | -$25.52M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$759.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.57M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.46M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.40M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.76M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.50M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.22M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.30M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.23M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.16M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.25M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.38M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.77M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.56M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.86M | – |
See a number that looks wrong?